Biopharmaceuticals
At the forefront of biopharmaceutical research, Shanghai Constream Biotechnology Co., Ltd. leverages superior antibody discovery technologies and platforms to power innovative drug development.
Core Technological Advantages
Our antibody discovery technology platform offers significantly improved screening efficiency compared to traditional methods. It allows for the rapid identification of high-quality antibodies targeting various disease targets, substantially reducing the time and cost of drug development. Furthermore, advanced molecular modification techniques optimize the selected antibodies, enhancing their stability and efficacy to ensure optimal performance in complex physiological environments.
Successful Project Experience
In past projects, we have collaborated with numerous well-known pharmaceutical companies. Utilizing our antibody discovery technology, we have successfully screened groundbreaking therapeutic antibodies for various project targets.
Cooperation and Results Transformation
The company actively engages in industry-academia-research collaborations with research institutions and pharmaceutical companies to accelerate the transformation of antibody discovery technology achievements. Through resource sharing and joint research and development, we have successfully applied numerous antibody discovery achievements to biopharmaceutical production. Currently, several biologics based on our antibody discovery technology are in clinical trials, promising to bring more effective treatment options to patients worldwide, demonstrating our innovative strength and industry leadership in the biopharmaceutical field.
Related Products
Recombinant human IFN gamma protein (his-tag)
Product Number: XC989997-500µg English Name: Recombinant Human IFN gamma Protein Chinese Name: 重组人 IFN gamma 蛋白
View DetailsRecombinant human IFN gamma protein (no tag)
Product Number: XC989996-500µg English Name: Recombinant Human IFN gamma Protein Chinese Name: 重组人 IFN gamma 蛋白
View DetailsWelcome your message